HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS

Molecular Cancer Research

Volumn 11, Issue 9, 2013, Pages 1072-1077

  Yang, Moon Hee ^a   Laurent, Gaelle ^b   Bause, Alexandra S ^b   Spang, Robert ^b   German, Natalie ^b   Haigis, Marcia C ^b   Haigis, Kevin M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTACTIN; GLYCOGEN SYNTHASE KINASE 3; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 6; K RAS PROTEIN; PROTEIN KINASE C ALPHA; SIRTUIN 2; SURVIVIN;

ACETYLATION; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL GROWTH; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ACETYLATION; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NIH 3T3 CELLS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIRTUIN 2;

EID: 84883555139     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0040-T     Document Type: Article

References (23)

1. Lau KS, Haigis KM. Non-redundancy within the RAS oncogene family: Insights into mutational disparities in cancer. Mol Cells 2009;28:315-20.
2. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70:5901-11.
3. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989;57:1167-77. (Pubitemid 19169813)
4. Sasaki AT, Carracedo A, Locasale JW, Anastasiou D, Takeuchi K, Kahoud ER, et al. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Signal 2011; 4:ra13.
5. Yang MH, Nickerson S, Kim ET, Liot C, Laurent G, Spang R, et al. Regulation of RAS oncogenicity by acetylation. Proc Natl Acad Sci USA 2012;109:10843-8.
6. You L, Nie J, Sun WJ, Zheng ZQ, Yang XJ. Lysine acetylation: enzymes, bromodomains and links to different diseases. Essays Biochem 2012;52:1-12.
7. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010;5:253-95.
8. Finley LW, Haas W, Desquiret-Dumas V, Wallace DC, Procaccio V, Gygi SP, et al. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PLoS ONE 2011;6:e23295.
9. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004;101:10380-5. (Pubitemid 38924934)
10. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417: 455-8. (Pubitemid 34563539)
11. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002;21:6820-31. (Pubitemid 36014554)
12. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003;22:1168-79. (Pubitemid 36313600)
13. Li Y, Shin D, Kwon SH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J 2012;280: 775-93.
14. Zhu J, Coyne CB, Sarkar SN. PKC alpha regulates Sendai virusmediated interferon induction through HDAC6 and beta-catenin. EMBO J 2011;30:4838-49.
15. Saji S,Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, et al. Significance ofHDAC6regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005;24:4531-9. (Pubitemid 41032616)
16. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 2008;68:7561-9.
17. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003;11:437-44. (Pubitemid 36293837)
18. Nahhas F, Dryden SC, Abrams J, Tainsky MA. Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. Mol Cell Biochem 2007;303:221-30. (Pubitemid 47261320)
19. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011;20:487-99.
20. Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ 2012;20:503-14.
21. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-8. (Pubitemid 23122749)
22. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989;86:8323-7. (Pubitemid 19286052)
23. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Exp Opin Invest Drugs 2000;9: 2767-82.